Nehlsen Anthony D, Lehrer Eric J, Dickstein Daniel R, Posner Marshall R, Misiukiewicz Krzysztof, Liu Jerry, Gupta Vishal, Bakst Richard L, Sharma Sonam
Radiation Oncology, Mount Sinai, New York, USA.
Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York City, USA.
Cureus. 2021 Jul 11;13(7):e16310. doi: 10.7759/cureus.16310. eCollection 2021 Jul.
Objectives Chemoradiation therapy (CRT) has been established as a standard treatment for locally advanced hypopharynx/larynx squamous cell carcinoma (SCC) but the role of induction chemotherapy (IC) remains unclear. The primary outcome of this study is to determine whether functional larynx-preservation survival (FLPS) is improved with the addition of IC in these patients. Secondary outcomes were overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and laryngectomy rates. Methods Records for patients with AJCC 8th edition clinical stage III-IVB laryngeal and hypopharyngeal SCC treated with CRT +/- IC from 2005-2019 were reviewed. FLPS was defined as time until death, progression, laryngectomy, or non-functional larynx. Kaplan-Meier curves were generated for FLPS, OS, PFS, and DMFS. Outcomes were compared using the stratified log-rank test. Laryngectomy rates were compared using Fisher's exact test. Results We included 52 patients with laryngeal and 38 with hypopharyngeal SCC (n=90); 19 patients with laryngeal SCC and 19 with hypopharyngeal SCC received IC (median three cycles). There were no differences in the three-year FLPS (61% vs 67.8%; p=0.88), OS (73.9% vs 86.2%; p=0.42), PFS (53.6% vs 62.6%; p=0.44), or DMFS (65.2% vs 71.5%, p= 0.85) between patients who did and did not receive IC all patients. Laryngectomy rates did not differ with and without IC (18.4 % vs 7.7%; p=0.19). Conclusion In this study of advanced laryngeal and hypopharyngeal SCC, IC did not improve three-year FLPS, OS, PFS, or laryngectomy rates compared to CRT alone. A large prospective series would provide a more robust understanding of the role of IC in this group of patients.
目的 放化疗(CRT)已被确立为局部晚期下咽/喉鳞状细胞癌(SCC)的标准治疗方法,但诱导化疗(IC)的作用仍不明确。本研究的主要结果是确定在这些患者中添加IC是否能提高功能性保喉生存率(FLPS)。次要结果包括总生存期(OS)、无进展生存期(PFS)、无远处转移生存期(DMFS)和喉切除术率。方法 回顾了2005年至2019年接受CRT±IC治疗的AJCC第8版临床III-IVB期喉和下咽SCC患者的记录。FLPS定义为直至死亡、进展、喉切除术或无功能喉的时间。生成FLPS、OS、PFS和DMFS的Kaplan-Meier曲线。使用分层对数秩检验比较结果。使用Fisher精确检验比较喉切除术率。结果 我们纳入了52例喉SCC患者和38例下咽SCC患者(n=90);19例喉SCC患者和19例下咽SCC患者接受了IC(中位三个周期)。接受和未接受IC的所有患者在三年FLPS(61%对67.8%;p=0.88)、OS(73.9%对86.2%;p=0.42)、PFS(53.6%对62.6%;p=0.44)或DMFS(65.2%对71.5%,p=0.85)方面没有差异。有无IC的喉切除术率没有差异(18.4%对7.7%;p=0.19)。结论 在这项晚期喉和下咽SCC的研究中,与单独使用CRT相比,IC并未提高三年FLPS、OS、PFS或喉切除术率。一个大型前瞻性系列研究将更有力地了解IC在这组患者中的作用。